A recent systematic review published in BMJ Evidence-Based Medicine examined the effectiveness of smartphone applications for smoking cessation. Researchers analyzed data from 31 randomized controlled trials involving more than 12,000 participants to determine whether digital health tools could help people quit smoking.
The study found that smokers using smartphone apps had higher success rates compared to those who received minimal or no support. In particular, the use of apps alongside traditional interventions such as pharmacotherapy and behavioral support led to higher abstinence rates than standard methods alone, though the certainty of this evidence was low.
The researchers noted: “While the authors note that the overall certainty of evidence for long-term continuous abstinence remains ‘low’ due to inconsistencies between studies, high attrition rates, reliance on self-reported data, and variability in sustained user engagement, the review underscores that the combination of pharmacotherapy and digital apps warrants further investigation in larger, higher-quality trials with longer follow-up and biochemical validation as a promising frontier in the quest to kick the cigarette habit.”
Tobacco use is recognized globally as a leading cause of preventable death. However, access to effective quitting resources is often limited by factors such as cost and geography. Traditional approaches have included face-to-face counseling and medications like nicotine replacement therapy or prescription drugs. Despite their effectiveness, these interventions are not widely used.
With widespread mobile technology adoption, digital health solutions are being considered as scalable options to address gaps in cessation support. Smartphone apps offer features unavailable through traditional therapies, including round-the-clock availability and interactive progress tracking.
Previous reviews struggled to establish app efficacy due to small sample sizes and inconsistent engagement. This latest review sought to fill that gap by aggregating recent trial data up until August 2025. The primary measure was six-month continuous abstinence—defined as self-reported non-smoking with only minimal lapses over six months—and secondary outcomes included seven-day point prevalence abstinence at various intervals.
Results indicated that smokers using apps alone were nearly three times more likely (relative risk 2.85) to remain abstinent at six months compared with those receiving little or no support—an absolute increase equivalent to 40 additional quitters per 1,000 users. When combined with medication-based treatments such as nicotine replacement therapy or varenicline, app users saw further increases in quit rates (relative risk 1.77), although differences across studies made it difficult to draw firm conclusions about magnitude.
Apps based on psychological-behavioral theories provided notable short-term benefits; users were 36% more likely to achieve seven-day abstinence at six months than those using other types of apps or controls. However, there is limited evidence regarding long-term effectiveness for these specific approaches.
The review concludes that while smartphone apps show promise as accessible tools for quitting smoking—especially when paired with established medical treatments—the quality and consistency of available evidence remains limited by variable study designs and self-reporting biases.
Further research is needed into how best to combine digital tools with existing therapies in order to maximize public health impact.
